Declared Dividend • Jun 08
Dividend increased to CN¥1.10 Dividend of CN¥1.10 is 22% higher than last year. Ex-date: 11th June 2026 Payment date: 11th June 2026 Dividend yield will be 5.1%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by earnings (79% earnings payout ratio) but not adequately covered by cash flows (96% cash payout ratio). The dividend has increased by an average of 14% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 31% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 28
First quarter 2026 earnings released: EPS: CN¥0.43 (vs CN¥0.38 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.43 (up from CN¥0.38 in 1Q 2025). Revenue: CN¥1.13b (up 10% from 1Q 2025). Net income: CN¥246.3m (up 14% from 1Q 2025). Profit margin: 22% (in line with 1Q 2025). Revenue is forecast to grow 9.3% p.a. on average during the next 2 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Announcement • Apr 28
Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2026 Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2026, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xinxian, Hebei China Announcement • Mar 30
Henan Lingrui Pharmaceutical Co., Ltd. to Report Q1, 2026 Results on Apr 28, 2026 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report Q1, 2026 results on Apr 28, 2026 Announcement • Dec 26
Henan Lingrui Pharmaceutical Co., Ltd. to Report Fiscal Year 2025 Results on Apr 28, 2026 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report fiscal year 2025 results on Apr 28, 2026 Reported Earnings • Oct 30
Third quarter 2025 earnings released: EPS: CN¥0.31 (vs CN¥0.29 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.31 (up from CN¥0.29 in 3Q 2024). Revenue: CN¥942.2m (up 10% from 3Q 2024). Net income: CN¥176.5m (up 9.8% from 3Q 2024). Profit margin: 19% (in line with 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year whereas the company’s share price has increased by 16% per year. Announcement • Sep 30
Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Oct 30, 2025 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report Q3, 2025 results on Oct 30, 2025 Reported Earnings • Aug 21
Second quarter 2025 earnings released: EPS: CN¥0.45 (vs CN¥0.39 in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.45 (up from CN¥0.39 in 2Q 2024). Revenue: CN¥1.08b (up 8.2% from 2Q 2024). Net income: CN¥257.6m (up 16% from 2Q 2024). Profit margin: 24% (up from 22% in 2Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 24% per year. Announcement • Jun 30
Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2025 Results on Aug 20, 2025 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report first half, 2025 results on Aug 20, 2025 Declared Dividend • Jun 16
Dividend increased to CN¥0.90 Dividend of CN¥0.90 is 13% higher than last year. Ex-date: 20th June 2025 Payment date: 20th June 2025 Dividend yield will be 3.8%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (68% earnings payout ratio) and cash flows (61% cash payout ratio). The dividend has increased by an average of 25% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 40% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Buy Or Sell Opportunity • Jun 13
Now 21% undervalued Over the last 90 days, the stock has risen 13% to CN¥23.64. The fair value is estimated to be CN¥29.96, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 8.9% over the last 3 years. Earnings per share has grown by 21%. Revenue is forecast to grow by 25% in 2 years. Earnings are forecast to grow by 23% in the next 2 years. Reported Earnings • Apr 27
First quarter 2025 earnings released: EPS: CN¥0.38 (vs CN¥0.34 in 1Q 2024) First quarter 2025 results: EPS: CN¥0.38 (up from CN¥0.34 in 1Q 2024). Revenue: CN¥1.02b (up 12% from 1Q 2024). Net income: CN¥216.8m (up 14% from 1Q 2024). Profit margin: 21% (in line with 1Q 2024). Revenue is forecast to grow 9.7% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 24% per year. Announcement • Apr 26
Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2025 Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2025, at 14:00 China Standard Time. Location: No. 666, Jiangjun Road, Xinxian County, Henan China Announcement • Mar 28
Henan Lingrui Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Apr 26, 2025 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report Q1, 2025 results on Apr 26, 2025 Announcement • Dec 27
Henan Lingrui Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on Apr 26, 2025 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report fiscal year 2024 results on Apr 26, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.27 in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.29 (up from CN¥0.27 in 3Q 2023). Revenue: CN¥853.1m (up 5.8% from 3Q 2023). Net income: CN¥160.8m (up 7.8% from 3Q 2023). Profit margin: 19% (in line with 3Q 2023). Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 21% per year whereas the company’s share price has increased by 25% per year. Price Target Changed • Oct 04
Price target increased by 10% to CN¥30.05 Up from CN¥27.25, the current price target is an average from 2 analysts. New target price is 21% above last closing price of CN¥24.78. Stock is up 38% over the past year. The company is forecast to post earnings per share of CN¥1.23 for next year compared to CN¥1.01 last year. New Risk • Sep 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.0% average weekly change). Announcement • Sep 30
Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report Q3, 2024 results on Oct 30, 2024 Valuation Update With 7 Day Price Move • Sep 27
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥22.66, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 134% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at CN¥43.46 per share. Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to CN¥18.79, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Pharmaceuticals industry in China. Total returns to shareholders of 95% over the past three years. Reported Earnings • Aug 13
Second quarter 2024 earnings released: EPS: CN¥0.39 (vs CN¥0.30 in 2Q 2023) Second quarter 2024 results: EPS: CN¥0.39 (up from CN¥0.30 in 2Q 2023). Revenue: CN¥997.0m (up 9.3% from 2Q 2023). Net income: CN¥222.7m (up 29% from 2Q 2023). Profit margin: 22% (up from 19% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has increased by 33% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Jun 28
Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 13, 2024 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report first half, 2024 results on Aug 13, 2024 Declared Dividend • Jun 17
Dividend of CN¥0.80 announced Shareholders will receive a dividend of CN¥0.80. Ex-date: 20th June 2024 Payment date: 20th June 2024 Dividend yield will be 3.1%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (73% earnings payout ratio) and cash flows (60% cash payout ratio). The dividend has increased by an average of 23% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 53% over the next 3 years, which should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 27
Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2023 results: EPS: CN¥1.01 (up from CN¥0.84 in FY 2022). Revenue: CN¥3.31b (up 10% from FY 2022). Net income: CN¥568.1m (up 22% from FY 2022). Profit margin: 17% (up from 16% in FY 2022). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 4.2%. Earnings per share (EPS) exceeded analyst estimates by 5.6%. Revenue is forecast to grow 15% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has increased by 37% per year, which means it is tracking significantly ahead of earnings growth. Announcement • Apr 27
Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024 Henan Lingrui Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2024, at 14:00 China Standard Time. Location: The Company's Meeting Room, Xinxian County, Henan China Announcement • Mar 29
Henan Lingrui Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Dec 29
Henan Lingrui Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 26, 2024 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report fiscal year 2023 results on Apr 26, 2024 Reported Earnings • Oct 29
Third quarter 2023 earnings released: EPS: CN¥0.27 (vs CN¥0.24 in 3Q 2022) Third quarter 2023 results: EPS: CN¥0.27 (up from CN¥0.24 in 3Q 2022). Revenue: CN¥806.1m (up 4.1% from 3Q 2022). Net income: CN¥149.2m (up 11% from 3Q 2022). Profit margin: 19% (up from 17% in 3Q 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 18% per year whereas the company’s share price has increased by 22% per year. Announcement • Sep 30
Henan Lingrui Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report Q3, 2023 results at 3:00 PM, China Standard Time on Oct 28, 2023 Reported Earnings • Aug 10
Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.25 in 2Q 2022) Second quarter 2023 results: EPS: CN¥0.30 (up from CN¥0.25 in 2Q 2022). Revenue: CN¥912.0m (up 11% from 2Q 2022). Net income: CN¥172.7m (up 24% from 2Q 2022). Profit margin: 19% (up from 17% in 2Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 14% per year. Buying Opportunity • May 05
Now 22% undervalued Over the last 90 days, the stock is up 26%. The fair value is estimated to be CN¥22.13, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 13% over the last 3 years. Earnings per share has grown by 18%. Revenue is forecast to grow by 32% in 2 years. Earnings is forecast to grow by 36% in the next 2 years. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: CN¥0.26 (vs CN¥0.24 in 1Q 2022) First quarter 2023 results: EPS: CN¥0.26 (up from CN¥0.24 in 1Q 2022). Revenue: CN¥788.6m (up 16% from 1Q 2022). Net income: CN¥144.2m (up 10% from 1Q 2022). Profit margin: 18% (in line with 1Q 2022). Revenue is forecast to grow 14% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 19% per year whereas the company’s share price has increased by 22% per year. Board Change • Nov 16
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 7 experienced directors. No highly experienced directors. 2 independent directors (5 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Reported Earnings • Oct 28
Third quarter 2022 earnings released: EPS: CN¥0.24 (vs CN¥0.20 in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.24 (up from CN¥0.20 in 3Q 2021). Revenue: CN¥774.3m (up 11% from 3Q 2021). Net income: CN¥134.8m (up 26% from 3Q 2021). Profit margin: 17% (up from 15% in 3Q 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 17% growth forecast for the Pharmaceuticals industry in China. Over the last 3 years on average, earnings per share has increased by 17% per year whereas the company’s share price has increased by 14% per year. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥13.56, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 20x in the Pharmaceuticals industry in China. Total returns to shareholders of 74% over the past three years. Buying Opportunity • Sep 16
Now 21% undervalued after recent price drop Over the last 90 days, the stock is down 6.9%. The fair value is estimated to be CN¥14.80, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Earnings per share has grown by 16%. Revenue is forecast to grow by 36% in 2 years. Earnings is forecast to grow by 47% in the next 2 years. Reported Earnings • Aug 11
Second quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.22 in 2Q 2021) Second quarter 2022 results: EPS: CN¥0.25 (up from CN¥0.22 in 2Q 2021). Revenue: CN¥820.6m (up 7.1% from 2Q 2021). Net income: CN¥139.7m (up 14% from 2Q 2021). Profit margin: 17% (in line with 2Q 2021). Over the next year, revenue is forecast to grow 18%, compared to a 23% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 15% per year. Reported Earnings • Apr 27
First quarter 2022 earnings: EPS and revenues miss analyst expectations First quarter 2022 results: EPS: CN¥0.24 (up from CN¥0.17 in 1Q 2021). Revenue: CN¥682.1m (up 16% from 1Q 2021). Net income: CN¥130.8m (up 35% from 1Q 2021). Profit margin: 19% (up from 16% in 1Q 2021). The increase in margin was driven by higher revenue. Revenue missed analyst estimates by 3.1%. Earnings per share (EPS) also missed analyst estimates by 8.9%. Over the next year, revenue is forecast to grow 23%, compared to a 26% growth forecast for the industry in China. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. 2 highly experienced directors. 2 independent directors (4 non-independent directors). Chairman of Supervisors Fukang Li was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Valuation Update With 7 Day Price Move • Mar 09
Investor sentiment deteriorated over the past week After last week's 17% share price decline to CN¥12.19, the stock trades at a forward P/E ratio of 15x. Average forward P/E is 24x in the Pharmaceuticals industry in China. Total returns to shareholders of 56% over the past three years. Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 17% share price gain to CN¥15.48, the stock trades at a forward P/E ratio of 19x. Average forward P/E is 23x in the Pharmaceuticals industry in China. Total returns to shareholders of 126% over the past three years. Valuation Update With 7 Day Price Move • Nov 17
Investor sentiment improved over the past week After last week's 16% share price gain to CN¥12.47, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 31x in the Pharmaceuticals industry in China. Total returns to shareholders of 64% over the past three years. Reported Earnings • Oct 28
Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.16 in 3Q 2020) The company reported a solid third quarter result with improved earnings and revenues, although profit margins were flat. Third quarter 2021 results: Revenue: CN¥697.6m (up 21% from 3Q 2020). Net income: CN¥107.1m (up 16% from 3Q 2020). Profit margin: 15% (in line with 3Q 2020). Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has only increased by 9% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Second quarter 2021 earnings released: EPS CN¥0.22 (vs CN¥0.18 in 2Q 2020) The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: CN¥766.1m (up 12% from 2Q 2020). Net income: CN¥123.1m (up 22% from 2Q 2020). Profit margin: 16% (up from 15% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 27
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥9.96, the stock trades at a trailing P/E ratio of 16.4x. Average trailing P/E is 30x in the Pharmaceuticals industry in China. Total returns to shareholders of 14% over the past three years. Reported Earnings • Apr 29
First quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.14 in 1Q 2020) The company reported a solid first quarter result with improved earnings and revenues, although profit margins were flat. First quarter 2021 results: Revenue: CN¥589.4m (up 20% from 1Q 2020). Net income: CN¥96.6m (up 26% from 1Q 2020). Profit margin: 16% (in line with 1Q 2020). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Jan 27
New 90-day low: CN¥7.91 The company is down 19% from its price of CN¥9.71 on 29 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 1.0% over the same period. Is New 90 Day High Low • Jan 11
New 90-day low: CN¥8.09 The company is down 26% from its price of CN¥10.88 on 13 October 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 1.0% over the same period. Is New 90 Day High Low • Dec 10
New 90-day low: CN¥9.11 The company is down 13% from its price of CN¥10.47 on 11 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 5.0% over the same period. Is New 90 Day High Low • Nov 24
New 90-day low: CN¥9.28 The company is down 15% from its price of CN¥10.96 on 26 August 2020. The Chinese market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 10.0% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥302.2m, up 3.4% from the prior year. Total revenue was CN¥2.22b over the last 12 months, up 3.1% from the prior year. Is New 90 Day High Low • Oct 23
New 90-day low: CN¥9.88 The company is down 10.0% from its price of CN¥10.96 on 24 July 2020. The Chinese market is up 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 3.0% over the same period. Announcement • Jul 08
Henan Lingrui Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 18, 2020 Henan Lingrui Pharmaceutical Co., Ltd. announced that they will report first half, 2020 results on Aug 18, 2020